Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Technical Presentation (February 2021)

8 slides from Aerie Pharmaceuticals's technical presentation, Feb 25, 2021

  1. Slide 1: Axitinib Implant (AR-14034) Overview

    Axitinib Implant (AR-14034) Overview February 2021 Exhibit 99.1

  2. Slide 2: Important Information

    For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

  3. Slide 3: 2019 U.S. Retinal Disease Market: Need for Reduced Injection Frequency, New MOAs

    For Investor Use 2019 U.S. Retinal Disease Market: Need for Reduced Injection Frequency, New MOAs Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 Frequent intravitreal injections required to maintain vision gains Represents a significant burden for patients and p

  4. Slide 4: Aerie's Proprietary Drug Delivery Platform for Retinal Disease – Predictable and Flexible

    For Investor Use Aerie’s Proprietary Drug Delivery Platform for Retinal Disease – Predictable and Flexible Customizable drug elution, reproducible manufacturing Proprietary bio-erodible formulations, PRINT ® manufacturing Longer treatment duration, reduced injection frequency Enables once or twice p

  5. Slide 5: Aerie's Proprietary Drug Delivery Technology: A Platform for Future Innovation

    For Investor Use Aerie’s Proprietary Drug Delivery Technology: A Platform for Future Innovation Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg wAMD DME RVO Dry AMD/GA Glaucoma Othe

  6. Slide 6: AR-14034 (Axitinib) Implant Opportunity

    AR-14034 (Axitinib) Implant Opportunity 1. Market Scope Estimates 2020; http://market-scope.com/ Aflibercept Ranibizumab Bevacizumab Brolucizumab Axitinib For Investor Use 2019 IVT anti-VEGF worldwide market $13B; est. $22B by 20251 Current anti-VEGF pipeline dominated by longer duration products ta

  7. Slide 7: Axitinib Is Preferred Small Molecule for VEGF Inhibition

    Axitinib Is Preferred Small Molecule for VEGF Inhibition Pan-VEGF receptor inhibitor (inhibits all isoforms of VEGF-R) Approved for systemic use in 2012 for the treatment of renal cell carcinoma Higher potency and less off-target activity than other small molecule inhibitors Most selective For Inves

  8. Slide 8: Axitinib Implant: Results Support Up to 12 Months Duration in Clinic

    Axitinib Implant: Results Support Up to 12 Months Duration in Clinic Proprietary polymer blend produces optimal drug elution profile Maintains high elution rate over time Drug release rate in rabbits predicts up to 12-months duration (once a year injection) in clinic Aerie rabbit data accurately pre

Aerie Pharmaceuticals — Technical Presentation (February 2021) on 6ix